- Home
- EMD vs LXRX Comparison
EMD vs LXRX Comparison
Compare EMD & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EMD | LXRX |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 626.1M | 703.3M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | EMD | LXRX |
|---|---|---|
| Price | $10.74 | $2.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.15 |
| AVG Volume (30 Days) | 164.3K | ★ 4.0M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 10.25% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $9.60 | $0.87 |
| 52 Week High | $11.30 | $2.67 |
Technical Indicators
Market Signals| Indicator | EMD | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.60 | 62.90 |
| Support Level | $10.61 | $1.52 |
| Resistance Level | $10.95 | $2.53 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 77.55 | 68.45 |
Price Performance
Historical ComparisonAbout EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management and long term investment company. The primary investment objective of the company is to seek high current income, and the secondary objective is to seek capital appreciation.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.